197 related articles for article (PubMed ID: 34217296)
1. Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells.
Peng Y; Huang Z; Zhou F; Wang T; Mou K; Feng W
Cell Commun Signal; 2021 Jul; 19(1):71. PubMed ID: 34217296
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.
Chen C; Zhuang Y; Chen X; Chen X; Li D; Fan Y; Xu J; Chen Y; Wu L
Oncotarget; 2017 Feb; 8(6):10025-10036. PubMed ID: 28036294
[TBL] [Abstract][Full Text] [Related]
3. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
Woessner DW; Lim CS
Mol Pharm; 2013 Jan; 10(1):270-7. PubMed ID: 23211037
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus.
Huang ZL; Gao M; Li QY; Tao K; Xiao Q; Cao WX; Feng WL
Oncotarget; 2013 Dec; 4(12):2249-60. PubMed ID: 24158537
[TBL] [Abstract][Full Text] [Related]
5. TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
Huang ZL; Gao M; Ji MS; Tao K; Xiao Q; Zhong L; Zeng JM; Feng WL
Amino Acids; 2013 Feb; 44(2):461-72. PubMed ID: 22782217
[TBL] [Abstract][Full Text] [Related]
6. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Wu LX; Xu JH; Zhang KZ; Lin Q; Huang XW; Wen CX; Chen YZ
Leukemia; 2008 Jul; 22(7):1402-9. PubMed ID: 18418407
[TBL] [Abstract][Full Text] [Related]
7. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
8. Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.
Li Q; Huang Z; Gao M; Cao W; Xiao Q; Luo H; Feng W
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257089
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
10. Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
Huang Z; Ji M; Peng Z; Huang S; Xiao Q; Li C; Zeng J; Gao M; Feng W
Biomed Pharmacother; 2011 Jun; 65(3):183-92. PubMed ID: 21641753
[TBL] [Abstract][Full Text] [Related]
11. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
George P; Bali P; Annavarapu S; Scuto A; Fiskus W; Guo F; Sigua C; Sondarva G; Moscinski L; Atadja P; Bhalla K
Blood; 2005 Feb; 105(4):1768-76. PubMed ID: 15514006
[TBL] [Abstract][Full Text] [Related]
12. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
Shiotsu Y; Neckers LM; Wortman I; An WG; Schulte TW; Soga S; Murakata C; Tamaoki T; Akinaga S
Blood; 2000 Sep; 96(6):2284-91. PubMed ID: 10979978
[TBL] [Abstract][Full Text] [Related]
13. The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia.
Zheng R; Wei W; Liu S; Zeng D; Yang Z; Tang J; Tan J; Huang Z; Gao M
Cell Commun Signal; 2024 Jun; 22(1):314. PubMed ID: 38849885
[TBL] [Abstract][Full Text] [Related]
14. Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.
Stella S; Tirrò E; Conte E; Stagno F; Di Raimondo F; Manzella L; Vigneri P
Mol Cancer Ther; 2013 Jun; 12(6):1085-98. PubMed ID: 23536723
[TBL] [Abstract][Full Text] [Related]
15. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
17. Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs.
Dixon AS; Constance JE; Tanaka T; Rabbitts TH; Lim CS
Pharm Res; 2012 Apr; 29(4):1098-109. PubMed ID: 22183511
[TBL] [Abstract][Full Text] [Related]
18. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
Wang J; Huang T; Sun J; Yu Y; Liu Z; Li W; Jia J; Chen C
Med Oncol; 2014 Aug; 31(8):112. PubMed ID: 25023053
[TBL] [Abstract][Full Text] [Related]
19. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
Zhu XS; Lin ZY; Du J; Cao GX; Liu G
Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
